Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 SCOUT-HCM trial evaluating Camzyos (mavacamten) in adolescents with symptomatic obstructive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE